Phase I, randomised, double-blind, placebo-controlled, single ascending dose (SAD) study evaluating the pharmacodynamics and tolerability of subcutaneous RM 131 in healthy volunteers
Latest Information Update: 18 Apr 2013
At a glance
- Drugs Relamorelin (Primary)
- Indications Diabetic gastroparesis
- Focus Adverse reactions; Pharmacodynamics
- 18 Apr 2013 New trial record